By Ajai Raj
For estrogen receptor (ER)-positive, HER2-negative breast cancer subtypes that are associated with a favorable prognosis, the 21-gene recurrence score (RS) assay may be unnecessary, according to investigators at Memorial Sloan Kettering Cancer Center, in New York City.
The investigators reviewed their institution’s database to identify subtypes with favorable prognosis. Data on RS for such subtypes are limited, they noted. The study cohort consisted of 57 women: 33 patients with